Increased regulatory requirements, complex protocols, and a global patient population make clinical trial recruitment increasingly difficult to forecast and manage, and many trials fail to enroll enough patients to finish on time. Delays in enrollment completion affect regulatory approval submissions and, ultimately, product launch. And budget and cost overruns combined with launch delays can cost a company hundreds of millions of dollars. But now, with DecisionView StudyOptimizer and Enrollment Benchmarks, there’s a better, more accurate way to predict enrollment performance.
DecisionView Enrollment Benchmarks
DecisionView Enrollment Benchmarks aggregate cross-industry performance data from clinical trials that have completed enrollment, providing valuable insight to help identify appropriate assumptions and enable more realistic planning and forecasting for similar studies. This information can be used to validate assumptions when planning for a specific study, or to benchmark enrollment performance across a portfolio of trials to determine areas for further operational improvements.
Enrollment Benchmarks are available to DecisionView StudyOptimizer customers who contribute their completed trial data, which is then aggregated and anonymized to ensure the confidentiality of sponsor studies. The breadth and depth of studies in the Enrollment Benchmarks data set will grow as participating sponsors complete additional studies, and as new contributors add their portfolios of completed trial data.
The benefits of DecisionView’s approach to aggregating enrollment benchmarks include:
For more information, please download our Datasheet.